Transcatheter Embolization And Occlusion Devices Market Size & Share 2025 – 2034

Transcatheter Embolization And Occlusion Devices Market Size

The global transcatheter embolization and occlusion devices market was valued at USD 5.3 billion in 2024 and is expected to exhibit growth at a CAGR of 8.3% from 2025 to 2034 period. The market for transcatheter embolization and occlusion (TEO) devices is witnessing strong growth due to an intersection of clinical, technological and demographic factors.

One of the most prominent factors is the increasing incidence of chronic diseases such as cancer, complicated pregnancies, vascular malformations and hemorrhagic disorders like hemophilia all of which tend to need specialized medical attention. With a global population that is aging, the need for quality of life procedures that lessen the invasiveness of surgery and duration of hospitalization is increasing which makes TEO devices favorable to both physicians and patients. 
 

Furthermore, the rising cases of liver cancer and hepatocellular carcinoma especially in the Asia Pacific region has led to the increased use of embolization therapies such as transarterial chemoembolization (TACE). Newer catheter, medical imaging, and biocompatible material technologies have improved the safety and accuracy of procedures and embolization therapy, guaranteeing more procedures are performed. Also, the increase in women suffering from uterine fibroids and their preference for uterine fibroid embolization (UFE) instead of a hysterectomy has further improved the market.
 

The widening application of TEO devices in Neuro-interventions, especially treating cerebral aneurysms and arteriovenous malformations, also fosters market growth positively. Increased patient and healthcare professionals awareness of embolization entails shorter recovery periods and fewer complications, further driving the demand. Furthermore, favorable reimbursement policies in developed regions along with a growing supply of interventional radiologists and catheterization laboratories worldwide are increasing procedural volumes. Strategic mergers and collaborations by major companies with designed diversification policies in expected product portfolios and targeted emerging markets also widen the scope of market growth. Altogether these factors accelerate innovation and adoption, augmenting the TEO devices market.
 

Transcatheter embolization and occlusion (TEO) devices are advanced surgical instruments that help to control excessive or pathological blood flow in the blood vasculature system. These devices consist of coils, plugs, microspheres, and liquids which are delivered through a catheter and are ideal for treating tumors, aneurysms, arteriovenous malformations, and uterine fibroids. Like other embolization procedures, TEO procedures are associated with less surgical trauma and shortened recovery time.
 

Transcatheter Embolization And Occlusion Devices Market Trends

There is a notable shift toward these procedures, which is a powerful factor fueling the transcatheter embolization and occlusion (TEO) devices market. Both patients and healthcare professionals are choosing to opt for minimally invasive treatments when compared to conventional open surgeries. This preference is due to significantly reduced post-operative pain, shorter recovery periods, and a lower chance of complications. TEO procedures, which utilize small ports for catheters insertion and deliver embolic agents through selective blood vessels, epitomize these trends.
 

• These procedures as well as surgically complicated gastrointestinal disorders, tumors, vascular abnormalities, peripheral aneurysms, and uterine fibroids can all be treated without extensive surgical manipulation. This paradigm shift in approach to healthcare greatly reduces the burden on strained healthcare systems in addition to achieving the ideal surgical outcome for the patient.
   
• Moreover, new developments in interventional radiology, imaging systems, as well as TEO device materials, make TEO procedures more precise, safe and applicable to a wider scope of medical specialties. The incorporation of contemporary catheter technologies along with the greater use of image-guided interventions is further optimizing procedural workflow and accuracy.
   
• Futhermore, as more patients and clinicians become informed about the benefits of receiving less invasive surgical techniques, the utilization for TEO devices is on the rise. Coupled with this is the global population which is aging and usually presents with more than one medical condition which makes them less ideal for significant surgery, further drives the need for these procedures.
   
• As healthcare systems around the globe transition to value-based care approaches, the economy-driven preference for TEO devices will increase, which are non invasive and cost-effective, thus, sustaining market expansion in the years to come.
   

Impact of Tariff on the Market

Taxes on medical devices such as manufacturing and selling transcatheter embolization and occlusion (TEO) devices can have severe repercussions on the worldwide market since they raise the cost of production and marketing. Greater taxes on imports of raw materials or completed goods could result in higher selling prices which restricts access to users, particularly in low-cost sensitive areas. These expenditures may slow the rate of procurement by hospitals and healthcare centers, and consequently, adoption rates.
 

In addition, international conflict and changes in regulations might interrupt supply chains, causing delays in the availability of products and hampering growth in these markets. They will have no choice but to revise their outsourcing and production plans, for example, relocating to regions without tariffs in order to remain competitive.
 

Transcatheter Embolization And Occlusion Devices Market Analysis

Based on device type, the market is bifurcated as non coil and coils. The non coil segment is expected to drive business growth and expand at a CAGR of 8.6%, reaching over USD 6.7 billion by 2034.
 

• Growth is primarily driven by the adoption of new embolic agents like microspheres and liquid embolics, along with plugs which provide superior control when occlusion is compared to traditional coil-based devices. Non-coil solutions are especially preferred in targeted embolization procedures used in treating liver cancer, arteriovenous malformations, gastrointestinal bleeding, and uterine fibroids. Because of their ability to negotiate complex vascular anatomies with consistent results, intervening radiologists have increasingly preferred these devices.
   
• Moreover, the non-coil devices’ safety profiles, along with their handling characteristics, have made them more versatile owing to ongoing advancements in material science and delivery systems. Also, non-coil devices used for precision-based procedures greatly help in the demand to non-coil embolic devices hence, supporting the latter.
   
• In addition, the global growth of this segment is supported by rising healthcare expenditure along with the increase in chronic diseases and the healthcare provider’s awareness of the benefits of non-coil embolization therapies.
   

Based on application, the transcatheter embolization and occlusion devices market is segmented as oncology, peripheral vascular disease, neurology, urology, and other applications. The oncology segment is expected to drive business growth and expand at a CAGR of 8.8%, reaching over USD 4.4 billion by 2034.
 

• This growth is primarily fueled by the global increasing burden of cancer, especially liver, kidney, and lung cancers that typically need more localized and less invasive treatment options. There has been significant growth in the adoption of transarterial chemoembolization (TACE) and radioembolization as vital interventional oncology procedures. The growing caseload of hepatocellular carcinoma, predominantly in the Asia Pacific and Latin America regions, is witnessing the greater use of embolization therapies.
   
• Also, the development of image-guided technologies along with new precise and safe embolic agents has made TEO procedures more reliable and safer, which has led to their increasing acceptance by oncologists and interventional radiologists. These procedures are appealing for the patients and the healthcare systems on account of shortened hospital stays and lessened side effects as well as an improved quality of life relative to conventional treatment options.
   
• Strong supportive policies for reimbursement coupled with increased international awareness of interventional oncology aided options is accelerating market growth. With the enduring threat of cancer as one of the primary causes of death across the globe, it is projected that the oncology sector will continue to be an important expansion region for the TEO devices industry.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the transcatheter embolization and occlusion devices market is classified into hospitals, ambulatory surgical centers, and other end users. The hospitals segment dominated the market with a revenue share of 62.6% in 2024.
 

• Hospitals are the primary centers for advanced interventional radiology and endovascular procedures, offering comprehensive infrastructure, skilled medical professionals, and access to cutting-edge imaging technologies required for TEO interventions. These facilities handle a high volume of patients with complex medical conditions such as cancer, aneurysms, gastrointestinal bleeding, and vascular malformations, conditions that often require embolization therapies.
   
• The availability of multidisciplinary teams, including interventional radiologists, oncologists, and vascular surgeons, enhances procedural success and safety, making hospitals the preferred setting for such treatments. Additionally, hospitals often benefit from better reimbursement frameworks and government funding, particularly in developed regions, which encourages the adoption of advanced devices and techniques.
   
• The rising incidence of chronic diseases, coupled with an aging population and growing awareness about minimally invasive treatment options, further boosts patient inflow for embolization procedures in hospital settings. Furthermore, the ongoing expansion of hospital networks, especially in emerging economies, and investments in technologically advanced hybrid operating rooms are strengthening the segment’s growth.
   
• Collectively, these factors solidify hospitals as the dominant end-user segment in the TEO devices market.
   

U.S. transcatheter embolization and occlusion devices market accounted for USD 1.8 billion in 2024 and is anticipated to grow at a CAGR of 7.4% between 2025 to 2034 period.
 

• Demand for embolization therapeutic devices (TEO) is greatly influenced by the widespread health issues such as cancer, gastrointestinal bleeding, aneurysms and uterine fibroids, which are treated optimally using minimally invasive embolization therapies. The dominating absolutes in healthcare spending, along with the sophisticated healthcare infrastructure of the U.S. facilitates the adoption of new TEO procedures.
   
• Furthermore, the increasing availability of leading market manufactures and incessant product development coupled with a surge in FDA approvals for new and efficient embolic agents and delivery systems fuels market growth. Along with these reasons, the higher life expectancy in the U.S. translates into a larger elderly population who are more likely to suffer from vascular and oncological ailments which further increases market demand.
   
• Increased expenses of the U.S. on healthcare and adoption of new technology also enhances the rapid growth of procedures in the country. This along with a greater focus on interventional TEO oncology and neurosurgery aids the U.S. market. Interventional radiology also benefits from improving investment policies directed towards surgical imaging making the market more attractive.
   

In Europe transcatheter embolization and occlusion devices market,  the UK is projected to grow remarkably in the coming years.
 

• Embolization procedures are commonly performed on chronic ailments like cancer, aneurysms, and uterine fibroids, making them a cornerstone driver. The UK’s advanced clamoring healthcare system and government endorsement of modern, less invasive devices is paving easier pathways for TEO device acceptance throughout hospitals and specialty clinics. Furthermore, the National Health Service (NHS) is adopting a more aggressive cost-centric approach towards treatment options focused on quick recovery and shorter duration of hospital admittance making TEO procedures a favorable choice.
   
• The demand for these procedures is bolstered by a rapidly growing elderly population, who are at a higher risk of suffering from vascular diseases and chronic conditions. In addition, the presence of some of the country's best medical device companies and vigorous clinical research into interventional radiology are stimulating awareness and innovation.
   
• The UK’s global leadership in training interventional radiologists, coupled with enhanced systems for imaging, is improving the accuracy and adoption of these procedures. All these factors combined position the UK as an emerging high-growth region in Europe for TEO devices in the imminent future.
   

China holds a dominant position in the Asia Pacific transcatheter embolization and occlusion devices market.
 

• Due to demographic, clinical and economic reasons, China dominates the Asia Pacific transcatheter embolization and occlusion (TEO) devices industry. Chronic ailments like cancer, aneurysms and vascular malformations are becoming increasingly common because of the country’s large and rapidly aging population, which also needs TEO procedures.
   
• Liver cancer, which is on the rise in China, is often treated with TACE, which increases the demand for embolization devices. In addition, the more widespread emergence of fibroids among women has increased the uptake of UFE owing to greater awareness of, and demand for, minimally invasive procedures.
   
• Government policies aimed at improving the healthcare system and increasing healthcare access, in addition to the expansion of healthcare technology and the domestic medical device industry, have market growth. Surgical TEO procedure reimbursement policies also form a large part of the market growth, alongside the growing number of interventional radiology fellowship programs. Local partnerships with international manufacturers have also improved the standard, availability and affordability of medical devices within China.
   

Transcatheter Embolization And Occlusion Devices Market Share

The top 5 companies in the market account for approximately 65% of market share, driven by their strong product portfolios, technological advancements, and extensive global distribution networks. As a result of spending a lot on research and development, performing strategic mergers and acquisitions, and innovating continuously, these other companies get to maintain their market position. Agile adoption of nex gen embolization technologies is made possible by strong clinical trial pipeline and the regulatory approvals it receives throughout several major areas.
 

Also, these companies enjoy established contacts with the hospitals, interventional radiologists, and even the healthcare systems as a whole, allowing these companies to enjoy passive product sales for long periods of time. They are also able to penetrate newly available markets internationally which have a growing surge in the requirements for minimally invasive operations. These dominant companies sustain industry standards as well as shape its dynamics by providing holistic solutions like delivery systems, imaging guidance tools, and most importantly, embolic agents which other companies have to comply with.
 

Transcatheter Embolization And Occlusion Devices Market Companies

Prominent players operating in the transcatheter embolization and occlusion devices industry include:

• Abbott
• acandis
• balt
• Boston Scientific
• COOK MEDICAL
• Edwards Lifesciences
• Johnson & Johnson
• LEPU MEDICAL
• Medtronic
• Merit Medical
• MicroVention
• Penumbra
• shape memory medical
• SIRTEX
• stryker
• TERUMO
   

USPs

• Abbott: Abbots remains remarkable because of their attention-grabbing embolic technologies and focus on innovation on which they expand their cardiovascular product portfolio as well as integrated imaging solutions designed to increase procedural accuracy. 
   
• Boston Scientific: The core of Boston Scientific’s business remains with a full array of embolization products including their strategic buys alongside their clinical deep dives which support customized care across neurovascular and peripheral vascular interventions.
   

Transcatheter Embolization And Occlusion Devices Industry News:

• In June 2022, Boston Scientific Corporation received FDA 510(k) clearance for its EMBOLD Fibered Detachable Coil, a device specifically engineered to reduce or block blood flow in the peripheral vasculature, offering a minimally invasive option for vascular interventions.
   
• In July 2021, Terumo Medical Corporation launched the AZUR Vascular Plug, the first of its kind designed for use with a microcatheter to occlude arteries up to 8mm in diameter. This innovative device enhances the effectiveness of peripheral vascular procedures by efficiently reducing or blocking arterial blood flow.
   

The transcatheter embolization and occlusion devices market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Device Type

• Non coil
  • Flow diverting devices
  • Embolization particles
  • Liquid embolics
  • Other non-coil device types
• Coils
  • Pushable coils
  • Detachable coils

Market, By Application

• Oncology
• Peripheral vascular disease
• Neurology
• Urology
• Other applications

Market, By End Use

• Hospitals
• Ambulatory surgical centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE